Premium
Surface‐Modified LPD Nanoparticles for Tumor Targeting
Author(s) -
LI SHYHDAR,
HUANG LEAF
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1348.001
Subject(s) - survivin , gene silencing , cancer research , downregulation and upregulation , rna interference , chemistry , liposome , apoptosis , cisplatin , genetic enhancement , microbiology and biotechnology , medicine , gene , chemotherapy , biology , rna , biochemistry
We have developed a tumor‐targeted LPD formulation (liposome‐polycation‐DNA complex) for siRNA. With surface modification, the targeted, PEGylated LPD increased the delivery efficiency by four‐fold and the gene‐silencing effect by two‐ to three‐fold. Downregulation of survivin in human lung cancer cells by targeted LPD induced 90% of apoptosis and sensitized the cells to cisplatin by four‐fold. PEGylated LPD formulation also significantly improved the tumor localization of siRNA in the NCI‐H460 human lung cancer xenograft model. The tumor appeared to be the major uptake organ for siRNA formulated in surface‐modified LPD. Our encouraging results indicate that surface‐modified LPD may be a potent carrier for RNAi‐based tumor therapy.